Full Press Release Details
Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III.
IMMP
Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III
Key Takeaway: Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III
Price reaction · baseline $4.4 (2021-10-27 close) · hit after-hours · 2 other IMMP headline(s) in the window, move may be shared
day 0 close · peak
-4.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)